Pipeline

Dystrogen Therapeutics is focused on the development of two technology platforms.

Candidates developed under Chimeric Cell platform:

• DEC - Duchenne Muscular Dystrophy Therapy
• Trimera - Sickle Cell Disease
• DYST 101 - Anti-Aging

Candidates developed under RNAi platform:

• DYST 201 - Huntington’s Disease